Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Complete Title: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (cilta-cel) Out-of- Specification (OOS) in Patients with Multiple Myeloma
Trial Phase: N/A
Investigator: Rahul Banerjee
The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications (cilta-cel out-of-specifications [OOS]) to appropriate adult participants (greater than or equal to 18 years) with relapsed/refractory multiple myeloma (MM).
Keywords:
- Multiple Myeloma (MM)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
N/A
Rahul Banerjee
RG1122744
NCT05346835
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (cilta-cel) Out-of- Specification (OOS) in Patients with Multiple Myeloma
Multiple Myeloma (MM)